Can cellular reprogramming cause cancer?
In our updated market reports, you will find everything you need
SUMMARY
Yes, cellular reprogramming can cause cancer when it pushes mature cells too far toward pluripotency or leaves them stranded in an unstable intermediate state.
The strongest evidence comes from animal experiments. Full OSKM reprogramming has produced multi-organ teratomas, germ-cell-like cancers and severe loss of normal tissue structure in mice.
Stopping the process early does not automatically solve the problem. Incomplete reprogramming has generated poorly differentiated tumors, including kidney growths resembling Wilms tumor, without requiring a large number of new genetic mutations.
Partial reprogramming is more promising than full reprogramming because useful rejuvenating effects can appear before a cell abandons its identity. Several controlled animal studies improved tissue function, molecular aging markers or survival without detecting tumors.
There is no universal safe dose. The outcome depends on the factors, delivery method, treatment schedule, tissue, age of the subject and mutations already present in the treated cells.
Removing c-MYC lowers one obvious source of oncogenic pressure, but it does not eliminate the underlying risk. OCT4, SOX2 and KLF4 can still loosen cell identity and drive cells toward pluripotency under the right conditions.
Localized treatment is the field’s most credible clinical starting point. The first human OSK program targets one eye, uses controlled activation and follows participants for years rather than attempting broad systemic rejuvenation.
Cancer is not the only serious failure mode. Sustained reprogramming has caused liver and intestinal failure in mice, while a recent chemical-reprogramming experiment produced metabolic toxicity instead of the expected rejuvenation benefit.
Older patients may present the hardest safety test because their tissues already contain mutations and small precancerous clones. Reprogramming could create an environment in which a previously contained damaged cell gains a growth advantage.
Localized partial reprogramming is credible enough for cautious trials against serious diseases, but its long-term cancer safety in humans remains unproven. Whole-body rejuvenation is much further away because it would expose vastly more cells, organs and hidden failure points.
What does cellular reprogramming actually mean?
Cellular reprogramming can describe several very different procedures, and the cancer risk changes sharply depending on how far the cell is pushed.
Full reprogramming uses factors such as OCT4, SOX2, KLF4 and c-MYC, usually shortened to OSKM, to turn an adult cell into an induced pluripotent stem cell. A pluripotent cell can produce almost any tissue in the body. Reaching that state requires the original cell to give up its previous identity.
Partial reprogramming stops earlier. Researchers try to reset some age-related changes while keeping a liver cell, muscle cell or neuron recognizably the same type of cell. Most rejuvenation research currently focuses on this narrower approach.
A third method fully reprograms cells outside the body. Scientists can then grow the cells, turn them into a specific cell type, check the batch and transplant the finished product. Direct lineage reprogramming takes another route by converting one mature cell type straight into another, such as a skin cell into a neuron.
We are mainly asking whether Yamanaka-factor reprogramming used for rejuvenation can cause cancer inside the body.
| Reprogramming method | What happens to the cell? | Main cancer concern |
|---|---|---|
| Full in vivo reprogramming | The mature cell reaches or approaches pluripotency | Teratomas, uncontrolled growth and loss of tissue structure |
| Partial in vivo reprogramming | Some age-related programs are reset while cell identity is preserved | Accidental dedifferentiation, abnormal intermediate cells and expansion of damaged clones |
| Ex vivo iPSC reprogramming | Cells are reprogrammed, differentiated and checked outside the body | Residual pluripotent cells and mutations acquired during laboratory growth |
| Direct lineage reprogramming | One mature cell type becomes another | Incorrect cell identity, poor conversion and context-specific abnormal growth |
Why is cellular reprogramming cancer risk a live question now?
Cellular reprogramming cancer risk has become an immediate clinical question because partial reprogramming has now entered human testing.
Life Biosciences recently treated the first participant in a Phase 1 trial of ER-100. The therapy delivers OCT4, SOX2 and KLF4 to retinal ganglion cells in people with glaucoma or non-arteritic anterior ischemic optic neuropathy. ClinicalTrials.gov lists a planned enrollment of up to 18 participants: 12 with glaucoma and six with the second condition.
Each participant receives one injection into one eye, followed by 56 days of doxycycline to switch on the treatment. The design includes ten clinic visits during the first six months and yearly monitoring through year five.
The setup shows how cautiously the field is moving. Researchers chose a small population, a confined organ, one treated eye, controlled activation and long follow-up. They are several steps away from attempting whole-body rejuvenation.
The trial has produced no meaningful cancer evidence yet. One participant, or even 18 participants, cannot reveal a rare tumor risk with confidence. What matters for now is that human exposure has begun under a tightly restricted protocol.
Why could cellular reprogramming promote cancer?
Cellular reprogramming can promote cancer because it loosens the controls that normally keep mature cells stable, specialized and relatively predictable.
A healthy retinal cell behaves like a retinal cell because thousands of genes are kept active or silent in a coordinated pattern. Reprogramming factors deliberately disturb that pattern. The cell becomes more flexible and begins moving away from its established identity.
Cancer cells often use the same flexibility. Many tumors contain cells that behave more like stem cells, switch between identities and survive treatments that kill more specialized cancer cells. Several reprogramming factors also participate in cancer-related pathways, with c-MYC being a particularly powerful driver of cell growth.
The overlap has limits. Researchers apply reprogramming factors for a planned purpose and, ideally, for a controlled period. Cancer develops through selection: cells carrying useful mutations or abnormal programs survive, multiply and gradually dominate their surroundings.
The practical concern is simple. A treatment designed to make an old cell more adaptable could occasionally make it too adaptable, especially when the cell already carries cancer-related mutations.
Has full cellular reprogramming already caused tumors?
Full cellular reprogramming has clearly caused tumors in animals, so the basic cancer concern rests on direct experimental evidence.
In a 2013 Nature study, researchers temporarily activated OSKM throughout genetically engineered mice. Teratomas appeared in several organs, including the pancreas, kidney, stomach and intestine. Cells also entered the bloodstream after losing their normal tissue identities.
Teratomas contain mixtures of tissue types because pluripotent cells can develop in many directions. Some teratomas are benign, while others contain malignant components. Even a benign teratoma would be unacceptable inside the brain, heart, eye or liver because the mass could destroy nearby tissue.
Later mouse work found an even more aggressive outcome. High OSKM expression erased normal genomic imprinting and produced cancers resembling human germ-cell tumors. The tumor cells continued growing after transplantation into other animals.
These experiments pushed cells far beyond the intended endpoint of modern rejuvenation treatments. They still settle one part of the debate: cellular reprogramming can produce genuine tumors when mature cells are driven too close to an embryonic state.
If you want more recent data on this point, please see our latest cellular reprogramming market report.
Can incomplete cellular reprogramming also cause cancer?
Incomplete cellular reprogramming can cause cancer-like growth because cells sometimes stop in an unstable state instead of returning safely to normal.
A 2014 Cell study switched on OSKM in mice and then stopped the treatment before full pluripotency developed. Tumors containing poorly differentiated cells later appeared in several tissues. Some kidney tumors closely resembled Wilms tumor, a childhood kidney cancer, in their appearance and gene activity.
The researchers found relatively few permanent genetic changes that could explain the tumors. Much of the dangerous behavior appeared to come from disrupted epigenetic programming: the instructions controlling which genes the cells used.
Another experiment combined early reprogramming with a cancer-causing KRAS mutation. Reprogramming suppressed the normal identity of pancreatic cells and dramatically accelerated pancreatic cancer development. The altered cells gave KRAS a more permissive environment in which to operate.
Together, these studies close an easy escape route. Stopping before pluripotency does not guarantee safety. The dangerous zone may include intermediate cells that have lost part of their old identity without reaching a stable new one.
Does partial cellular reprogramming avoid cancer?
Partial cellular reprogramming has avoided detectable tumors in several animal studies, although every successful result depends on a specific dose, schedule, tissue and delivery system.
The most influential early study used brief cycles of OSKM in mice with a premature-aging disorder. Two days of factor expression were followed by five days without expression. Median lifespan increased by about 33%, several aging-related features improved, and the researchers reported no teratomas during the treatment schedule.
Researchers later tested transient reprogramming in naturally aged mice. Different experiments reported younger molecular patterns in tissues including the skin, kidney, muscle and brain. A gene-therapy study using OSK also reported longer remaining lifespan in old wild-type mice without an observed rise in tumors.
Local OSK expression in mouse retinal ganglion cells produced another important result. The treatment supported nerve regeneration and improved visual function while preserving the cells’ retinal identity.
The animal evidence shows that useful biological effects can appear before full reprogramming. That makes partial reprogramming scientifically credible. Cancer safety remains specific to each protocol because modest changes in timing or tissue exposure have produced very different outcomes elsewhere.
| Experimental approach | Main finding | What we can conclude |
|---|---|---|
| Continuous systemic OSKM | Teratomas, organ damage and early death | Strong exposure is unsafe |
| Cyclic OSKM in prematurely aged mice | Improved aging features and about 33% longer median lifespan | A tumor-free operating window can exist |
| Transient reprogramming in naturally aged mice | Younger molecular patterns in several tissues | Partial effects also occur outside progeria models |
| Local OSK in retinal cells | Nerve regeneration and improved visual function | Targeted OSK can work without obvious loss of identity |
| OSK gene therapy in old wild-type mice | Longer remaining lifespan without reported tumors | Longer exposure studies are possible, although replication remains essential |
If you want more recent data on this point, please see our latest cellular reprogramming market report.
How narrow is the safe window for partial cellular reprogramming?
The safe window for partial cellular reprogramming appears narrow enough that treatment duration alone cannot define it.
In a study of naturally aged human cells, researchers delivered reprogramming factors through short-lived messenger RNA. Their full protocol usually began activating endogenous pluripotency programs around the fifth day and produced iPSC colonies after roughly 12 to 15 daily treatments. They stopped the rejuvenation experiment after four days.
The treated cells showed younger gene-expression, inflammatory and regenerative patterns while retaining their original identities. That four-day boundary worked for those cells, factors and laboratory conditions. A different cell type could move faster or slower.
Cells within the same tissue also respond unevenly. After identical exposure, some may barely change, some may reach the desired younger state, and a small minority may travel much further toward dedifferentiation. Average measurements can hide that minority.
For a clinical treatment, the useful dose will need to be defined through cell-state measurements. Researchers must track lineage markers, pluripotency genes, abnormal cell division and persistent changes after the treatment is switched off. Counting treatment days provides only part of the answer.
Does removing c-MYC make cellular reprogramming safe?
Removing c-MYC should lower the cancer risk of cellular reprogramming, but OSK still has enough power to disrupt cell identity.
c-MYC is one of the best-known human oncogenes. It stimulates growth, metabolism and cell division, and abnormal MYC activity appears across many cancer types. Leaving c-MYC out of a rejuvenation treatment is therefore a sensible first safety measure.
Several prominent programs now use OCT4, SOX2 and KLF4 alone. The current human eye trial follows this OSK approach, as did the earlier mouse experiments that restored visual function.
The remaining three factors still require caution. OCT4 and SOX2 help maintain stem-cell identity, while KLF4 can either suppress or support tumor growth depending on the tissue and surrounding mutations. OSK can also achieve pluripotency under suitable laboratory conditions without externally supplied c-MYC, partly because cells already contain related growth pathways.
Removing c-MYC reduces one major source of proliferative pressure. The broader dedifferentiation risk remains, so factor choice must be combined with strict control over location, duration and dose.
Does local cellular reprogramming make cancer less likely?
Local cellular reprogramming should make cancer less likely because far fewer cells and organs are exposed.
A treatment delivered into one eye affects a vastly smaller biological area than a therapy circulating through the entire body. The eye can also be examined repeatedly with high-resolution imaging, allowing doctors to spot structural changes earlier than they could in many internal organs.
Before entering human testing, Life Biosciences reported OSK expression in selected retinal regions of nonhuman primates after an injection into the eye. The company also tested the treatment in primates with an optic-nerve injury designed to resemble human disease.
ER-100 follows the same containment strategy in people. The study treats a single eye and increases doses gradually, with an independent safety board reviewing the first participant at each new dose before additional participants receive it.
Local delivery still leaves room for serious harm. An abnormal growth inside the eye could damage vision, and small amounts of the vector may reach unintended tissues. The trial therefore measures viral shedding, immune responses and vector distribution alongside standard eye examinations.
Local treatment gives researchers a manageable starting point. Whole-body reprogramming would multiply the number of exposed cells, potential failure points and organs requiring long-term surveillance.
If you want more recent data on this point, please see our latest cellular reprogramming market report.
Are some organs more vulnerable to cellular reprogramming?
The liver and intestine appear especially vulnerable to systemic cellular reprogramming, with severe toxicity developing well before tumors become visible.
In one mouse model, sustained OSKM expression caused rapid weight loss, liver dysfunction, intestinal damage and early death. Researchers then created mice in which the factors stayed inactive in the liver and intestine. The animals tolerated longer treatment and showed fewer severe effects.
A newer study examined the liver failure in more detail. Prolonged OSKM activation caused liver cells to lose parts of their identity, accumulate oxidative stress and stop functioning properly. Treatment with the antioxidant N-acetylcysteine improved survival, although it did not turn sustained systemic reprogramming into a clinically acceptable procedure.
These results add an important correction to a cancer-only discussion. A reprogramming treatment can become lethal through organ failure before cancer has time to develop.
Tissue turnover may help explain the difference. The intestine constantly replaces its cells, while the liver reacts strongly to injury and regeneration signals. Those properties could make both organs unusually sensitive to forced changes in identity. Neurons and other slowly dividing cells face different hazards, including loss of function even without rapid cell growth.
A safety result from the eye, muscle or skin therefore tells us little about how the same factors would behave in the liver or intestine.
Could cellular reprogramming help hidden precancerous cells grow?
Cellular reprogramming could help hidden precancerous cells grow, and this risk becomes more relevant when treating older people.
Human tissues accumulate mutations throughout life. Many older adults carry small populations of cells with cancer-related mutations without having cancer. These cells remain controlled by competition with neighboring cells, immune surveillance and intact growth barriers.
Reprogramming changes that environment. Cells must cope with altered gene expression, metabolism, chromatin structure and identity. A mutation that offers little advantage under normal conditions could become valuable during that stress.
Pluripotent stem-cell cultures provide a clear example of this selection. Researchers studying 140 human embryonic stem-cell lines found cancer-associated TP53 mutations in five independent lines. The mutant cells became more common as the cultures were repeatedly expanded. A wider review of published sequencing data uncovered additional TP53 mutations.
Laboratory culture differs from brief reprogramming inside a person, so those numbers cannot be turned into a human risk estimate. The underlying mechanism remains relevant: reprogramming can create conditions in which a rare damaged cell outgrows healthier cells.
Clinical studies aimed at older patients will eventually need to measure clonal changes before and after treatment. Absence of a visible tumor during the first months would leave this slower risk unresolved.
Is chemical cellular reprogramming safer than using reprogramming genes?
Chemical cellular reprogramming may avoid some gene-delivery risks, but recent animal evidence shows that small molecules can create their own forms of toxicity.
Chemical cocktails aim to alter the same cellular programs as transcription factors without inserting or delivering OSK or OSKM genes. Researchers can adjust the dose, stop treatment quickly and potentially manufacture the compounds like conventional medicines.
Promising cell-culture experiments found that chemical combinations could lower transcriptomic or epigenetic age measurements and alter mitochondrial activity. Moving those cocktails into living animals has proved harder.
A recently published study tested a seven-compound reprogramming cocktail in genetically diverse aged mice. The treatment enlarged mitochondria and increased several measures of mitochondrial activity, yet it also caused a harmful buildup of lipid droplets. The metabolic toxicity blocked the expected rejuvenation benefit.
The experiment did not show that chemical reprogramming causes cancer. It did show why “gene-free” and “safe” cannot be treated as synonyms. Small molecules may affect many tissues at once, hit unintended molecular targets and remain difficult to confine to the desired cells.
Chemical reprogramming could eventually offer a more controllable route. Today, the in vivo evidence is too early and inconsistent to rank it as safer than targeted OSK delivery.
If you want more recent data on this point, please see our latest cellular reprogramming market report.
Is ex vivo cellular reprogramming safer than reprogramming cells inside the body?
Ex vivo cellular reprogramming is easier to control because scientists can inspect the cells before a patient receives them.
A manufacturer can reprogram cells into iPSCs, turn them into retinal cells, neurons or heart cells, and then test the finished batch. Abnormal chromosomes, cancer-related mutations, poor differentiation and remaining pluripotent cells can trigger rejection of the batch.
Raw iPSCs are generally unsuitable for transplantation because even a small number can produce teratomas. The therapeutic product must contain highly purified, differentiated cells.
Laboratory growth introduces its own pressure. Cells that divide faster can gradually take over a culture, and mutations affecting genes such as TP53 may give cells a competitive advantage. Long culture periods also increase opportunities for chromosomal changes and other abnormalities.
Ex vivo production replaces an uncontrolled in-body process with a manufacturing and quality-control problem. That trade is valuable because defective cells can be discarded before treatment. Screening still has limits, especially when a rare abnormal cell escapes detection or the transplanted cells behave differently in a living tissue.
Compared with systemic in vivo rejuvenation, ex vivo therapy currently offers the clearer path to measuring and reducing tumor risk.
How would doctors detect dangerous cellular reprogramming early?
Doctors would need to detect dangerous cellular reprogramming before a visible tumor forms, using markers of identity loss, abnormal growth and expanding mutant clones.
A tumor usually appears late in the process. Earlier warning signs could include activation of pluripotency genes such as NANOG, disappearance of normal tissue markers, unusual combinations of cell identities or persistent cell division after the treatment ends.
Single-cell sequencing is becoming particularly useful here. Bulk tissue analysis produces an average result across thousands or millions of cells. A rare population moving toward a dangerous state may disappear inside that average. Single-cell methods can reveal small groups following the wrong developmental path.
Imaging and biopsies can add information where the organ allows them. Blood-based DNA tests may eventually detect expanding clones or genetic material released by abnormal cells, although sensitivity will vary greatly by tissue.
Monitoring also needs to continue for years. A short course of reprogramming factors may leave lasting epigenetic changes, while a mutant clone could require a long period to become clinically visible.
The first human trials are appropriately designed around safety. Larger studies will need more sophisticated monitoring than standard adverse-event reporting if researchers want to quantify a rare cancer risk.
Which safeguards reduce cellular reprogramming cancer risk most?
Cellular reprogramming becomes safer when several independent controls limit which cells are treated, how strongly they respond and how long the response lasts.
Removing c-MYC reduces direct oncogenic pressure. Local administration and tissue-specific promoters shrink the exposed population. Short-lived delivery methods prevent indefinite factor production, while inducible systems allow researchers to switch the treatment off.
Modern single-cell tools can test whether treated cells retain the correct identity. Future treatments may also include synthetic safety circuits that stop factor expression or destroy a cell when pluripotency markers appear.
No safeguard covers every failure mode. A reversible treatment may still cause an irreversible cellular change. A tissue-specific promoter can leak into unwanted cells. A local injection can spread beyond its target.
The most convincing design will combine containment, reversibility, monitoring and a way to remove cells that cross an unsafe boundary.
| Safeguard | Cancer risk it reduces | Remaining weakness |
|---|---|---|
| Removing c-MYC | Strong growth and oncogenic stimulation | OSK can still loosen cell identity |
| Local administration | Exposure across multiple organs | Nearby and off-target cells may still be reached |
| Tissue-specific promoters | Expression in the wrong cell types | Promoter specificity is rarely perfect |
| Short-lived mRNA or controlled activation | Prolonged factor expression | Brief exposure can leave lasting changes |
| Single-cell identity monitoring | Small populations entering abnormal states | Routine sampling of every treated cell is impossible |
| Genomic and clonal screening | Expansion of cancer-associated mutations | Easier for ex vivo products than internal organs |
| Shutdown or suicide circuits | Survival of cells that become unsafe | Added biological complexity creates new failure points |
What evidence would prove partial cellular reprogramming is safe enough?
Partial cellular reprogramming will look safe enough only after long studies show that the benefits clearly outweigh the tumor and organ-toxicity risks for one specific use.
Naturally aged animals should carry more weight than young or prematurely aged models. Old tissues contain more mutations, chronic inflammation and small precancerous clones. Cancer-prone animal models can reveal whether treatment accelerates a disease that was already beginning.
Researchers also need repeated-dose experiments, high-dose experiments and observation periods long enough to capture delayed tumors. Full pathology should cover every organ reached by the vector, including organs that were exposed unintentionally.
Human evidence will arrive in stages. A small eye trial can show whether one localized OSK treatment causes obvious short-term harm. Larger and longer studies can estimate less common complications. Neither result would automatically support repeated treatment throughout a healthy person’s body.
The acceptable risk also depends on the disease. A patient facing irreversible blindness may reasonably accept uncertainty that would be unacceptable for a healthy person seeking general rejuvenation.
Systemic anti-aging use requires the highest standard because the treatment would expose many organs while offering no immediate rescue from a fatal or disabling condition.
Can cellular reprogramming cause cancer?
Yes, cellular reprogramming can cause cancer and other dangerous tumors when it pushes cells too far or leaves them in an unstable intermediate state.
Full OSKM reprogramming has produced multi-organ teratomas and germ-cell-like cancers in mice. Prematurely stopped reprogramming has caused dysplastic tumors resembling childhood kidney cancer. Early reprogramming has also accelerated pancreatic cancer when combined with a KRAS mutation.
Partial reprogramming deserves a more precise verdict. Several carefully controlled protocols have improved tissue function, aging markers and even mouse survival without detectable tumors. These results show that rejuvenation can begin before cells lose their identity completely.
The boundary is still poorly mapped. The outcome changes with the factors, dose, schedule, tissue, delivery method, age of the animal and mutations already present in the treated cells. Recent studies have also exposed severe liver and metabolic toxicity, reminding us that cancer is only one possible failure.
Our final judgment is direct: localized partial reprogramming is credible enough for cautious trials against serious diseases, but its cancer safety remains unproven in humans. Whole-body rejuvenation is much further away. Researchers have found ways to lower the danger; they have yet to show that millions or trillions of older human cells can be made younger without occasionally making some of them dangerously unstable.
If you want more recent data on this point, please see our latest cellular reprogramming market report.
OUR METHODOLOGY
This analysis examines whether cellular reprogramming can cause cancer and whether controlled partial reprogramming has reduced that danger enough to justify human testing. We separate full in vivo reprogramming, partial in vivo reprogramming, ex vivo iPSC production and direct lineage conversion because they expose patients to different failure modes.
We evaluate the evidence across the factors that materially change the outcome: how far cells move from their original identity, whether OSK or OSKM is used, treatment duration, delivery method, tissue exposure, subject age, pre-existing mutations and what happens after factor expression stops.
We treat experiments producing tumors under intense or prolonged OSKM exposure as proof that reprogramming can cause cancer, not as direct estimates of the risk from a localized modern treatment. In the other direction, studies reporting no tumors are treated as protocol-specific safety evidence rather than proof that partial reprogramming is generally safe.
Animal studies in naturally aged subjects carry more weight for rejuvenation safety than studies limited to young animals or premature-aging models. Older tissues contain more accumulated mutations, inflammation and precancerous clones, making them closer to the population likely to receive an age-related treatment.
We also include organ failure, abnormal intermediate cell states, metabolic toxicity and clonal expansion. A protocol can become dangerous long before doctors see a visible tumor, and a short observation period may miss changes that take years to become clinically apparent.
The ER-100 trial registration is used to describe the first human exposure to targeted OSK reprogramming, including its enrollment, one-eye treatment design, doxycycline-controlled activation and long-term follow-up. The trial can identify obvious early safety problems, but its small size cannot establish the rate of a rare cancer complication.
Key sources include the ClinicalTrials.gov registration for the ER-100 Phase 1 trial, the Nature study on in vivo OSKM reprogramming and multi-organ teratomas, the Cell study on tumors following prematurely terminated reprogramming, the Cell study on cyclic partial reprogramming in a progeria mouse model, and the Nature Aging study of partial reprogramming in naturally aged mice.
Additional sources include the Nature Communications study on transient reprogramming of aged human cells, the Nature study on OSK-mediated restoration of visual function, the Nature Aging study on liver and intestinal failure during sustained reprogramming, the Nature analysis of TP53-mutant selection in pluripotent stem-cell cultures, and the Nature Communications review of partial-reprogramming evidence and translational limits.
Our conclusion comes from the combined direction of these results rather than one decisive experiment. The evidence establishes that reprogramming can generate tumors, shows that carefully controlled protocols can produce rejuvenating effects without detectable tumors, and leaves unresolved whether that boundary can be maintained reliably across older human tissues and long periods of follow-up.
Related blog posts
- Which startup looks most promising in reversing cellular aging?
